Prognostic utility of secretory phospholipase A 2 in patients with stable coronary artery disease

Clinical Chemistry

Volumn 57, Issue 9, 2011, Pages 1311-1317

  O'Donoghue, Michelle L ^a   Mallat, Ziad ^b,c   Morrow, David A ^a   Benessiano, Joelle ^d   Sloan, Sarah ^a   Omland, Torbjørn ^e   Solomon, Scott D ^a   Braunwald, Eugene ^a   Tedgui, Alain ^b,c   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; PLACEBO; SECRETORY PHOSPHOLIPASE A2; TRANDOLAPRIL; TROPONIN T;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; STROKE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL ENZYME TESTS; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; INDOLES; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NECROSIS; PHOSPHOLIPASES A2, SECRETORY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; STROKE;

EID: 80052236376     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.166520     Document Type: Article

References (18)

1. Mallat Z, Lambeau G, Tedgui A. Lipoproteinassociated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010;122:2183-200.
2. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoproteinassociated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-44.
3. Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem 2002;277:29116-24.
4. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999;19:1284-90. (Pubitemid 29227649)
5. Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007;27: 600-6.
6. -/- mice. J Cardiovasc Pharmacol 2009;53: 60-5.
7. -/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 2009; 50:623-9.
8. Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD. Effects of 1-H-indole- 3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (plasma study): a phase II double-blind, randomised, placebocontrolled trial. Lancet 2009;373:649-58.
9. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351: 2058-68.
10. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
11. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2463-9. (Pubitemid 350203965)
12. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44: 837-45.
13. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007;27:1177-83. (Pubitemid 46641976)
14. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2005;25:839-46. (Pubitemid 40463879)
15. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005;46:1249-57. (Pubitemid 41615545)
16. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-4. (Pubitemid 29440119)
17. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, Chen JH. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1824-32.
18. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009;30:2742-8.